The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivative (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except: (A) Artemether plus lumefantrine, (B) Artesunate plus quinine, (C) Artesunate plus pyrimethamine-sulfadoxine, (D) Artesunate plus mefloquine
Answer is B. The WHO recommended ACTs include:

Artemether-lumefantrine
Artesunate-amodiaquine
Artesunate-mefloquine
Artesunate-sulfadoxine-pyrimethamine
Dihydroartemisinin-piperaquine